Primary care diabetes, Год журнала: 2025, Номер unknown
Опубликована: Апрель 1, 2025
Obesity and type 2 diabetes mellites (T2DM) are intertwined epidemics that continue to pose significant challenges global public health. We aim review the available evidence on metabolic effects of tirzepatide, focusing weight loss maintenance lost weight, body composition alterations, appetite regulation, glycemic control, lipid profile modulation. Tirzepatide administration for 72 weeks elicited reduction ranging from 5 % 20.9 across different trials in a dose-dependent manner. Furthermore, limited showed may be primarily due fat mass reduction. also significantly decreased food intake, reduced overall scores increased fasting visual analog scale satiety fullness clinical trials. Moreover, tirzepatide exhibited favorable with notable reductions HbA1c levels 20.4 mmol/mol mg dose 28.2 15 dose, following treatment durations lasting 40-52 weeks. Additionally, exerts beneficial impact parameters, including total cholesterol, low-density lipoprotein triglyceride levels, while increasing high-density cholesterol concentrations. Despite its efficacy, is associated gastrointestinal adverse effects, which requires escalation strategies enhance tolerability. Mild moderate events commonly reported at higher doses, discontinuation rates 4 10 dosages. In conclusion, has shown multifaceted along manageable profiles, makes it promising therapeutic agent addressing both obesity T2DM. However, further long-term randomized controlled warranted reveal efficacy safety outcomes, particularly diverse patient populations.
Язык: Английский